Zealand Pharma Loses Fifth of Value After Trial Dropouts
Danish biotech Zealand Pharma saw its stock slide after disclosing a 20% dropout rate in its weight-loss drug trial d...
Knowing when to switch from passive to active strategies can boost returns. This guide outlines practical signals, costs, and risk considerations.
27,240 articlesDanish biotech Zealand Pharma saw its stock slide after disclosing a 20% dropout rate in its weight-loss drug trial d...
Three U.S. utility stocks are delivering reliable dividend income as rate-base growth supports earnings, offering a d...
Asset managers reevaluating security are treating safety features as a core lever to stabilize NOI and attract tenant...
A new wave of consolidation is reshaping fintech markets as AI integration and healthier balance sheets spur potentia...
A four-position, ultra-high-yield plan claims to generate over $1,000 in monthly passive income from a $100,000 start...
Two fresh upgrades lifted Intel shares as Jim Cramer proclaimed the company the top name in chips. The stock surged, ...
A disrupted energy flow landscape is lifting a U.S. midstream stock and with it the focus on safe, high-yield income....
Rivian's R2 rollout marks a new chapter for the EV maker. This guide breaks down whether the stock deserves a place i...
A single ETF quietly powered a decade of returns, turning $10,000 into close to $100,000. This article breaks down ho...
Palantir stock soared today as investors priced in a mix of solid results, new government and enterprise wins, and a ...
A Bitcoin-native DeFi project is winding down amid weak demand, underscoring a broader hurdle for BTC yield ecosystem...
At VivaTech in Paris, Jeff Bezos argues AI will expand the labor force, not shrink it. The piece explores how this vi...